Comparison of serum levels of asymmetric dimethylarginine between patients who take two types of atypical antipsychotics

Maryam Safaei1,2,3, Ali Akhondpoor Manteghi2, Najmeh Shahini4, Amir Hooshang Mohammadpour*5,6

Received: 28 Apr 2017                  Published: 23 Oct 2019

Abstract

Background: Schizophrenia is associated with increased cardiovascular morbidity. Asymmetric dimethylarginine (ADMA) has been suggested as a cardiovascular biomarker. Treatment with atypical antipsychotics can increase some traditional risk factors of coronary artery disease. In addition to traditional risk factors, this study is carried out as a comparison of serum levels of ADMA and non-traditional factors among patients who take two types of atypical antipsychotics.

Methods: In this clinical study, 57 schizophrenic patients with multiple episodes and 20 healthy voluntaries that fulfilled inclusion and exclusion criteria were entered into the study. The patients were divided into 3 groups (18 patients received risperidone alone, 20 patients received clozapine alone and 19 patients did not receive any drug). Plasma concentrations of ADMA, high-sensitivity C-reactive protein (hs-CRP) and homocysteine were measured through enzyme-linked immunosorbent assay (ELISA), and traditional risk factors of metabolic syndrome were measured.

Results: Mean age of participants was 46.08±12.54 years. Moreover, the traditional (High-density lipoprotein (HDL), total cholesterol, waistline, and Body Mass Index (BMI)) and non-traditional factors (Homocysteine, hs-CRP) and ADMA were higher in patients with schizophrenia compared to healthy group (p≤ 0.05). Also, in the clozapine group, all mentioned non-traditional factors and ADMA were significantly higher than other groups (p≤ 0.05).

Conclusion: In the clozapine group, levels of non-traditional factors and ADMA were significantly higher which indicates these patients are at higher risk of cardiovascular disease.

Keywords: Asymmetric dimethylarginine, Atypical antipsychotics, Metabolic syndrome, Schizophrenia

Introduction

Asymmetric dimethylarginine (ADMA) is a competitive inhibitor of nitric oxide synthase (NO) and inhibits the production of pathologic levels of vascular NO. Its intra-arterial administration can lead to local vasoconstriction. ADMA has been suggested as a cardiovascular biomarker in previous studies, and its serum level was found to be increased in patients with coronary artery disease and metabolic syndrome (1). Hypertension and hypercholesterolemia (2, 3), type 2 diabetes, insulin resistance, hyperhomocysteinemia, aging, and obesity (2, 4-6) are among the risk factors for atherosclerosis in which an increase in ADMA has been reported.

In combination with Framingham risk score, the traditional risk factors can be appropriate predictors of cardio-

What is “already known” in this topic:

Treatment with atypical antipsychotics can increase traditional risk factors of coronary artery disease, and in many studies clozapine and olanzapine were at the top of the list of the atypical antipsychotics.

→ What this article adds:

In clozapine group, levels of non-traditional factors (hs-CRP, Homocysteine) and ADMA were significantly higher which indicates these patients are at higher risk of cardiovascular disease.
Serum levels of asymmetric dimethylarginine between patients who receive antipsychotics (7, 15, 16).

Cysteine and increased metabolic syndrome in patients with a history of multiple episodes and 20 healthy volunteers without any traditional or nontraditional risk factors. The age range of samples was 23 to 78 years. 70% were men, and 30% were women. The results showed that the mean±SD age was 46.08±12.54 years. 70% were men, and 30% were women. The results showed that the mean±SD age was 46.08±12.54 years. Descriptive statistics of the traditional, ADMA and nontraditional factors in four groups are showed in Table 1.

Methods

Patients

In this clinical study, 57 patients with schizophrenia with a history of multiple episodes and 20 healthy volunteers that fulfilled inclusion and exclusion criteria were entered into the study and were divided into four groups as below:

1. 18 schizophrenic patients received risperidone alone for at least five months.
2. 20 schizophrenic patients received clozapine alone for at least five months.
3. 19 schizophrenic patients that did not receive any antipsychotic for at least five months.
4. 20 healthy volunteers without any traditional or nontraditional cardiovascular risk factors.

Inclusion criteria consisted of schizophrenic patients receiving the atypical antipsychotic for at least 5 months and not receiving other antipsychotics or drugs with effect on ADMA, in combination with studied antipsychotics. In another study (19) this period of time was considered three months, and we increased into five months. All of their patients experienced more than one relapse (19).

Exclusion criteria consisted of any disease during the study that could distort the results, lack of patient’s cooperation to continue studying, unavailability of patients after the inclusion, any hepatic or renal disorders, metabolic syndrome, cancer, infection, chronic inflammatory disease, and any other drug with an effect on ADMA.

Blood sampling and ADMA assay

After inclusion, the patients’ demographic characteristics and history of the disease were recorded in a questionnaire, and 10 mL blood was collected from them. 5 mL was used for traditional factors of metabolic syndrome, and the remaining 5 mL was centrifuged at 1500 rpm, and the serum was removed and stored at -70 °C. The serum ADMA concentration was measured through ELISA, and CRP and homocysteine levels were measured.

Traditional factors include fasting blood sugar (FBS), HDL cholesterol (mmol/L), low-density lipoprotein (LDL) cholesterol (mmol/L), triglycerides (TG) (mmol/L), total cholesterol (mmol/L), diastolic blood pressure (DBP) (mmHg), systolic blood pressure (SBP) (mmHg), waistline and body mass index. Nontraditional factors include hs-CRP and homocysteine.

Ethical considerations

The study approved by the Ethics Committee of Mashhad University of Medical Science. Informed consent was obtained from the parents of all patients. In all steps of research, medical confidentiality and privacy were respected.

Statistical analysis

Data were analyzed using SPSS21. Normality of the quantitative variables was determined using Kolmogorov-Smirnov test. For comparison of ADMA levels among the four groups, one-way ANOVA and Tukey Post-Hoc tests were carried out. A≤0.05 was considered as statistical significance.

Results

Population study

In this clinical study, 18 patients were included in the risperidone group, 20 patients in the clozapine group, 19 patients in the schizophrenia group with no medication in the past five months, and 20 patients in the control group (healthy subjects). The age range of samples was 23 to 78 years. 70% were men, and 30% were women. The results showed that the mean±SD age was 46.08±12.54 years. Descriptive statistics of the traditional, ADMA and nontraditional risk factors in four groups are showed in Table 1.

Comparison of traditional risk factors between groups

According to Table 1 traditional factors including FBS, LDL, DBP, SBP, and TG did not have significant differences between four groups. For other traditional factors containing BMI, Cholesterol, HDL and Waistline Tukey Post Hoc test was done in Table 2.
The results presented in Table 2 indicate that, BMI has a significant difference in schizophrenic patients without any drug compared with risperidone and clozapine group. According to Table 1, BMI is lower in schizophrenic participants without any drug group.

HDL has a significant difference in the healthy control group compared with the risperidone group and schizophrenic participants without any drug group. According to Table 1, HDL is lower in the healthy group.

Cholesterol has a significant difference in the healthy group compared with risperidone and clozapine group. According to Table 1, Cholesterol is considerably lower in the healthy group.

Waistline is significantly lower in schizophrenic participants without any drug compared with other three groups.

The results presented in Table 3 showed that: Homocysteine is significantly different in the clozapine group compared with the other three groups, and according to Table 1, it is considerably higher in the clozapine group. Also, hs-CRP is significantly different in risperidone group in comparison with the other three groups, and according to Table 1, it is noticeably higher than schizophrenic participants without any drug group and the healthy group. Also, ADMA is significantly different in the clozapine group compared with the other three groups, and according to Table 1, it is considerably higher in the clozapine group. Moreover, ADMA and non-traditional variables have significant differences between the four groups (Table 1). Serum concentrations of ADMA were compared in groups. In the clozapine group compared with three other groups all three factors (ADMA, hs-CRP, Homocysteine) were significantly higher (p<0.05). Also, hs-CRP in the group receiving risperidone compared to the control group and group without treatment was significantly higher (p<0.05) (Table 3).

### Table 1. Comparison of data of traditional and non-traditional factors and ADMA among four groups

<table>
<thead>
<tr>
<th>Variable</th>
<th>Risperidone group</th>
<th>Clozapine group</th>
<th>Schizophrenic participants without any drug</th>
<th>Healthy group</th>
<th>p*1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fasting blood sugar</td>
<td>103.06±10.17</td>
<td>121.40±40.72</td>
<td>95.1±12.35</td>
<td>101.65±15.77</td>
<td>0.06</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/L)</td>
<td>54.06±10.82</td>
<td>50.50±14.53</td>
<td>55.79±13.16</td>
<td>40.50±10.46</td>
<td>0.001</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/L)</td>
<td>99.50±19.28</td>
<td>97.20±19.61</td>
<td>89.63±26.99</td>
<td>81.40±26.00</td>
<td>0.075</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>118.67±57.43</td>
<td>147.20±115.19</td>
<td>95.1±51.71</td>
<td>99.25±54.40</td>
<td>0.094</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>178.72±30.35</td>
<td>177.85±31.35</td>
<td>158.53±45.84</td>
<td>145.55±28.61</td>
<td>0.009</td>
</tr>
<tr>
<td>Diastolic blood pressure</td>
<td>71.39±6.37</td>
<td>70.30±6.86</td>
<td>71.32±8.30</td>
<td>73.75±7.41</td>
<td>0.534</td>
</tr>
<tr>
<td>Systolic blood pressure</td>
<td>115.28±7.37</td>
<td>113.75±8.09</td>
<td>112.98±10.31</td>
<td>115.75±7.30</td>
<td>0.693</td>
</tr>
<tr>
<td>Waistline</td>
<td>90.56±19.15</td>
<td>95.40±16.07</td>
<td>71.68±6.73</td>
<td>88.30±12.00</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Body Mass Index</td>
<td>26.78±6.79</td>
<td>25.45±4.83</td>
<td>20.14±3.08</td>
<td>24.04±3.42</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Homocysteine</td>
<td>6.64±3.07</td>
<td>9.21±3.60</td>
<td>6.72±2.60</td>
<td>4.49±1.20</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>hs-CRP</td>
<td>2.16±0.77</td>
<td>3.07±1.17</td>
<td>1.90±1.45</td>
<td>0.83±0.61</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ADMA</td>
<td>1.77±0.54</td>
<td>2.56±1.01</td>
<td>1.22±0.35</td>
<td>1.13±0.44</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Data are presented as mean±SD

*p, ** 95% CI

### Table 2. Comparison of traditional factors among four groups

<table>
<thead>
<tr>
<th>Group</th>
<th>BMI</th>
<th>Cholesterol</th>
<th>HDL</th>
<th>Waistline</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risperidone group</td>
<td>Nodrug</td>
<td>&lt;0.001(2.45 to 10.84)**</td>
<td>0.44(-13.08 to 53.47)</td>
<td>0.99(-3.11 to 9.65)</td>
</tr>
<tr>
<td>Healthy</td>
<td>0.35(1.39 to 6.88)</td>
<td>0.90(0.31 to 6.04)</td>
<td>0.01(2.12 to 24.80)</td>
<td>0.98(10.0 to 14.51)</td>
</tr>
<tr>
<td>Clozapine group</td>
<td>Nodrug</td>
<td>0.89(-2.80 to 5.47)</td>
<td>1.00(-31.99 to 33.74)</td>
<td>0.90(-7.68 to 14.80)</td>
</tr>
<tr>
<td>Healthy</td>
<td>0.89(-5.47 to 2.80)</td>
<td>0.99(-33.74 to 31.99)</td>
<td>0.90(-14.80 to 7.86)</td>
<td>0.80(-7.41 to 17.10)</td>
</tr>
<tr>
<td>Clozapine participants without any drug</td>
<td>Nodrug</td>
<td>-0.01(-1.08 to -2.45)</td>
<td>0.44(-53.47 to 13.08)</td>
<td>0.99(-6.95 to 13.11)</td>
</tr>
<tr>
<td>Healthy</td>
<td>0.04(-9.39 to -1.22)</td>
<td>0.46(-51.73 to 13.08)</td>
<td>0.67(-5.79 to 16.37)</td>
<td>&lt;0.001(-35.80 to -11.63)</td>
</tr>
<tr>
<td>Healthy group</td>
<td>Nodrug</td>
<td>0.06(-0.18 to 7.09)</td>
<td>0.79(-45.38 to 19.43)</td>
<td>0.002(-26.37 to -4.21)</td>
</tr>
<tr>
<td>Healthy</td>
<td>0.35(-6.88 to 1.39)</td>
<td>0.04(-66.04 to -0.31)</td>
<td>0.01(-24.80 to 2.32)</td>
<td>0.98(-14.51 to 10.00)</td>
</tr>
<tr>
<td>Healthy</td>
<td>0.86(-5.44 to 2.62)</td>
<td>0.04(-64.29 to -0.31)</td>
<td>0.09(-20.94 to 0.94)</td>
<td>0.46(-19.03 to 4.83)</td>
</tr>
</tbody>
</table>

*p, ** 95% CI

### Table 3. Comparison of ADMA and non-traditional factors among four groups

<table>
<thead>
<tr>
<th>Group</th>
<th>Homocysteine</th>
<th>hs-CRP</th>
<th>ADMA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risperidone group</td>
<td>Nodrug</td>
<td>0.99*(2.52 to 2.37)**</td>
<td>0.01(0.16 to 1.96)</td>
</tr>
<tr>
<td>Healthy</td>
<td>0.10(-0.26 to 4.56)</td>
<td>0.00(0.44 to 2.21)</td>
<td>0.07(0.03 to 1.30)</td>
</tr>
<tr>
<td>Clozapine group</td>
<td>Nodrug</td>
<td>0.03(-4.98 to -0.14)</td>
<td>0.04(-1.80 to -0.02)</td>
</tr>
<tr>
<td>Healthy</td>
<td>0.03(-0.14 to 4.98)</td>
<td>0.04(0.02 to 1.80)</td>
<td>0.01(0.12 to 1.46)</td>
</tr>
<tr>
<td>Clozapine participants without any drug</td>
<td>Nodrug</td>
<td>&lt;0.001(2.36 to 7.06)</td>
<td>&lt;0.001(1.37 to 3.10)</td>
</tr>
<tr>
<td>Healthy</td>
<td>0.07(-0.15 to 4.61)</td>
<td>0.92(-0.61 to 1.13)</td>
<td>0.99(-0.57 to 0.74)</td>
</tr>
<tr>
<td>Healthy</td>
<td>1.00(-2.37 to 2.52)</td>
<td>0.92(-0.61 to 1.13)</td>
<td>0.99(-0.57 to 0.74)</td>
</tr>
<tr>
<td>Clozapine</td>
<td>Nodrug</td>
<td>0.03(-4.87 to -0.10)</td>
<td>&lt;0.001(-2.85 to -1.10)</td>
</tr>
<tr>
<td>Healthy</td>
<td>0.04(-6.45 to 0.26)</td>
<td>0.92(-1.13 to 6.61)</td>
<td>0.99(-0.74 to 0.57)</td>
</tr>
<tr>
<td>Healthy</td>
<td>Clozapine</td>
<td>&lt;0.001(-7.06 to -2.36)</td>
<td>&lt;0.001(-3.10 to -1.37)</td>
</tr>
</tbody>
</table>

*p, ** 95% CI
Discussion

This study is the first study comparing ADMA, traditional and non-traditional factors between patients who take two types of atypical antipsychotics in comparison with a control group. The results showed that the serum level of ADMA was significantly higher in schizophrenic patients who take clozapine than all of the other groups and there was no significant difference between schizophrenic patients without treatment and the healthy group. Also, there was no significant difference between the risperidone group and the other groups (except for the clozapine group) in ADMA level.

Nitric oxide is a free radical with some effects: vasodilation, antithrombosis, and inhibition of clot formation; and ADMA is a competitive inhibitor of nitric oxide synthetase and a vascular injury biomarker. So, we can say that clozapine injures the vascular endothelium more than other antipsychotics and according to previous studies, clozapine causes atherosclerosis more than other antipsychotics (20). Thus clozapine causes vascular injury and so can increase ADMA that is similar to our results.

In this study the groups matched in terms of ADMA increasing factors as much as possible. On the other hand, because schizophrenia increases ADMA itself, we consider a group with schizophrenia and without any drug (group 3). So if we see different ADMA levels in groups, it is of high probability because of drugs.

In a study on schizophrenic patients, ADMA was clearly higher in the group with the history of several episodes than the first episode (19). So, we selected patients for all of the groups from the patients with several episodes.

In another study, ADMA level in patients with the first episode was significantly increased compared to the control group. ADMA was measured again after two months of treatment with antipsychotics which showed a significant decrease compared to the initial level. There was no relationship between the level of ADMA and the severity of disease (22, 23). So we consider a no-drug schizophrenic group, but in our study, there was no significant difference between no-drug patients and healthy group.

There was also a statistically significant difference between the control group compared to clozapine receiving schizophrenia patients and the no-drug group in terms of ADMA, and this is consistent with the study of Das (24), Celik (19), and Zincir (22). However, the study of Jorgenersen et al. (14) showed no difference between various groups.

The results of this study showed that patients with schizophrenia treated with clozapine had a higher ADMA than the control group. Furthermore, ADMA level was reduced in schizophrenic patients group that did not consume any drug during the last 5 months. This is also similar to the study of Celik et al. (9, 19).

In another study, short-term treatment initially creates a protection against endothelial damage which may be due to reduced agitation and activity of the autonomic nervous system, but no significant association was found between the disease severities (9). This study showed that drug consumption is a factor which increases possible risk factors in heart disease (14).

In our study, homocysteine in schizophrenic patients who take clozapine was significantly higher than other groups, and there was no significant difference between schizophrenic patients without treatment and healthy group. Also, there was no significant difference between the risperidone group and other groups (except clozapine group) in homocysteine level.

These results are not consistent with those of Adam Wysokin’ski study (20), but was similar to the study of Shusuke Numata et al. (25). It seems that homocysteine reducing strategies are effective in patients with schizophrenia particularly those receiving clozapine, and this reduction has been proven through consumption of folate, B12, and pyridoxine. Reduction of this factor is effective in reducing the risk of cardiovascular diseases in patients with schizophrenia (18, 25, 26).

Some studies have indicated higher levels of homocysteine and risk of metabolic syndrome in patients receiving antipsychotics, that is similar to our study (7, 15, 16).

In our study, hs-CRP in patients who take clozapine was significantly higher than other groups. hs-CRP in patients who take risperidone was significantly higher than the healthy group and schizophrenic without treatment group. There was no significant difference between healthy group and patients without treatment group in hs-CRP level.

A study was carried out in 2010 on the effects of haloperidol, risperidone, and olanzapine antipsychotics on CRP. Three months after receiving the drug, CRP level in patients receiving haloperidol was 92.7% higher than risperidone receiving patients (17). However, in our study among the investigated atypical antipsychotics, clozapine was associated with a significantly higher CRP than risperidone.

In our study, there were some statistically significant differences between schizophrenia patients and the control group in terms of traditional factors of FBS, BMI, cholesterol, LDL, and waistline that is similar to the study of Blażej Misiak (27). In addition, the drug-receiving groups had higher total cholesterol levels than the other two groups, and this was also consistent with the study of Blażej Misiak (27).

Generally, in our study, there was a little significant difference in traditional factors among our groups. It is probably because of the exclusion criteria as we excluded patients with metabolic syndrome.

Conclusion

The traditional factors including High-density lipoprotein, total cholesterol, waistline, and Body mass index, and non-traditional factors including Homocysteine, hs-CRP and ADMA were higher in patients with schizophrenia compared to healthy group (p-value ≤ 0.05). Moreover, in the clozapine group, all mentioned non-traditional factors and ADMA were significantly higher than other groups (p≤ 0.05).

Limitation

We couldn’t match the mean ages of the groups. Due to the fact that the patients had chronic schizophrenia for a long time, we couldn’t match the groups in terms of dos-
M. Safaei, et al.

Age and duration of treatment for each drug.

Acknowledgments
The authors would like to thank Pharmacologic Sciences Research Center of Ferdowsi University of Medical Sciences and Behavioural Sciences Research Center of Ibn-e-Sina Hospital. Voluntary participation and cooperation of the medical students in the study is highly appreciated.

Funding
This work was extracted from residency thesis in the Mashhad University of medical science and without any organizational financial support.

Conflict of Interests
The authors declare that they have no competing interests.

References

http://mjiri.iums.ac.ir